Years of Life Lost Due to Air Pollution in Switzerland: A Dynamic Exposure-Response Model

2005 ◽  
Vol 34 (5) ◽  
pp. 1029-1035 ◽  
Author(s):  
Martin Röösli ◽  
Nino Künzli ◽  
Charlotte Braun-Fahrländer ◽  
Matthias Egger

2018 ◽  
Vol 7 (3) ◽  
pp. 158-165 ◽  
Author(s):  
Ying Zhang ◽  
Michael A. Tortorici ◽  
Dipti Pawaskar ◽  
Ingo Pragst ◽  
Thomas Machnig ◽  
...  

2017 ◽  
Vol 57 (7) ◽  
pp. 843-854 ◽  
Author(s):  
Rik Schoemaker ◽  
Janet R. Wade ◽  
Armel Stockis

2007 ◽  
Vol 19 (6-7) ◽  
pp. 483-494 ◽  
Author(s):  
William F. McDonnell ◽  
Paul W. Stewart ◽  
Marjo V. Smith

2021 ◽  
Vol 12 ◽  
Author(s):  
Huanhuan Wang ◽  
Xiaoyun Hu ◽  
Teng Wang ◽  
Cheng Cui ◽  
Ji Jiang ◽  
...  

Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa clinical trial were used in the model: 10 sepsis patients from the placebo group and a total of 24 sepsis patients from the 0.06 mg/kg, 0.12 mg/kg, and 0.24 mg/kg drug groups. Exposure-response relationship was constructed to model the impact of the standard care therapy and area under curve (AUC) of kukoamine B to the disease biomarker (SOFA score). The model was evaluated by goodness of fit and visual predictive check. The simulation was performed 1,000 times based on the built model.Results: The data of the placebo and the drug groups were pooled and modeled by a nonlinear mixed-effect modeling approach in sepsis. A latent-variable approach in conjunction with an inhibitory indirect response model was used to link the standard care therapy effect and drug exposure to SOFA score. The maximum fraction of the standard care therapy was estimated to 0.792. The eliminate rate constant of the SOFA score was 0.263/day for the standard care therapy. The production rate of SOFA score (Kin) was estimated at 0.0569/day and the AUC at half the maximal drug effect (EAUC50) was estimated at 1,320 h*ng/mL. Model evaluation showed that the built model could well describe the observed SOFA score. Model-based simulations showed that the SOFA score on day 7 decreased to a plateau when AUC increased to 1,500 h*ng/mL.Conclusion: We built an exposure-response model characterizing the pharmacological effect of kukoamine B from the standard care therapy in sepsis patients. A dose regimen of 0.24 mg/kg was finally recommended for the Phase IIb clinical trial of kukoamine B based on modeling and simulation results.


2002 ◽  
Vol 35 (1) ◽  
pp. 72-79 ◽  
Author(s):  
M. Mebust ◽  
D. Crawford-Brown ◽  
W. Hofmann ◽  
H. Schöllnberger

Sign in / Sign up

Export Citation Format

Share Document